Zobrazeno 1 - 10
of 265
pro vyhledávání: '"Josef Thaler"'
Autor:
Larissa Ruhe, Sonja Heibl, Manfred Czompo, Johannes Haybaeck, Jürgen Loskutov, Manuela Johanna Regenbrecht, Josef Thaler, Lena Wedeken, Christian René Alexander Regenbrecht
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 490-496 (2024)
Introduction: Controlled randomized trials, molecular analytics, and guideline recommendations have so far been irreplaceable tools to ensure appropriate treatment and decision-making for physicians and patients. Individual patient models are increas
Externí odkaz:
https://doaj.org/article/389f7ad980334d7a930d50912475fae7
Autor:
Gudrun Piringer, Florian Ponholzer, Josef Thaler, Thomas Bachleitner-Hofmann, Holger Rumpold, Alexander de Vries, Lukas Weiss, Richard Greil, Michael Gnant, Dietmar Öfner
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeThe aim of this retrospective analysis was to determine if the response to preoperative radio(chemo)therapy is predictive for survival among patients with locally advanced rectal cancer and may act as a potential surrogate endpoint for disease
Externí odkaz:
https://doaj.org/article/977558b1eea44721904fb4c3a84050de
Autor:
Bernhard Doleschal, Hossein Taghizadeh, Gerald Webersinke, Gudrun Piringer, Georg Schreil, Jörn Decker, Karl J. Aichberger, Patrick Kirchweger, Josef Thaler, Andreas Petzer, Clemens A. Schmitt, Gerald W. Prager, Holger Rumpold
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic options, especially after the failure of first-line systemic treatment. Targeted treatments for this clinical situation are promising and have entered cl
Externí odkaz:
https://doaj.org/article/fc727f94f62e4a3b8cc484f4f3a2aff9
Autor:
Yawen Dong, Jonas Santol, Birgit Gruenberger, Alfred Lenauer, Friedrich Laengle, Josef Thaler, Gudrun Piringer, Wolfgang Eisterer, Angela Djanani, Judith Stift, Thomas Gruenberger
Publikováno v:
Cancers, Vol 16, Iss 5, p 857 (2024)
In 2007, the ASSO-LM1 trial, a multicenter prospective study, was initiated to investigate the resectability (R0) rate following preoperative combination therapy with XELOX and bevacizumab in patients with potentially resectable colorectal liver meta
Externí odkaz:
https://doaj.org/article/3370f126caab4bdab811a651fcdf8d0a
Autor:
Gudrun Piringer, Thomas Gruenberger, Josef Thaler, Irene Kührer, Klaus Kaczirek, Friedrich Längle, Istvan Viragos-Toth, Arno Amann, Wolfgang Eisterer, Reinhold Függer, Johannes Andel, Angelika Pichler, Judith Stift, Lidija Sölkner, Michael Gnant, Dietmar Öfner
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundTwenty percent of colorectal cancer liver metastases (CLMs) are initially resectable with a 5-year survival rate of 25%–40%. Perioperative folinic acid, 5-fluorouracil, oxaliplatin (FOLFOX) increases progression-free survival (PFS). In ad
Externí odkaz:
https://doaj.org/article/a086fc5f438c457e89f61feead205633
Autor:
Gudrun Piringer, Jörn Decker, Vera Trommet, Thomas Kühr, Sonja Heibl, Konrad Dörfler, Josef Thaler
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAFV600
Externí odkaz:
https://doaj.org/article/34a3375093144d3a96d52ef838ce889b
Autor:
Claus-Henning Köhne, Meinolf Karthaus, Laurent Mineur, Josef Thaler, Marc Van den Eynde, Javier Gallego, Reija Koukakis, Marloes Berkhout, Ralf-Dieter Hofheinz
Publikováno v:
Drugs in R&D, Vol 19, Iss 3, Pp 267-275 (2019)
Abstract Objective Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer were retrospectively analysed to investigate the effects of primary tumour location a
Externí odkaz:
https://doaj.org/article/e5ea3fd307224aeab0e585693366cc17
Autor:
Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, Hans G. Derigs, Mark-Oliver Zahn, Christine Geffriaud-Ricouard, Max Gueldner, Christine Windemuth-Kieselbach, Stefanie Pederiva, Pierre Bohanes, Felicitas Scholten, Gudrun Piringer, Josef Thaler, Roger von Moos
Publikováno v:
Cancers, Vol 14, Iss 14, p 3522 (2022)
Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of this regimen in
Externí odkaz:
https://doaj.org/article/168ffa2b661549d49b7749d43682f49b
Autor:
Gudrun Piringer MD, MSc, Bernhard Holzner MD, Beate Mayrbaeurl MD, Sonja Heibl MD, Monika Sztankay MD, Sophie Frantal, Michael Gnant MD, Josef Thaler MD
Publikováno v:
Integrative Cancer Therapies, Vol 19 (2020)
Purpose: Cancer and its treatment strategies can have adverse effects on physical functioning and quality of life. Treatment strategies for better quality of life are still an unresolved issue. Physical activity is a promising treatment strategy that
Externí odkaz:
https://doaj.org/article/cebf3090581c4a5cabefc18de1d78ab2
Autor:
Florian Huemer, Josef Thaler, Gudrun Piringer, Hubert Hackl, Lisa Pleyer, Clemens Hufnagl, Lukas Weiss, Richard Greil
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background In metastatic colorectal cancer (mCRC), the localization of the primary tumour has been shown to be of prognostic as well as predictive relevance. Methods With the aim to investigate clinical and molecular disease characteristics
Externí odkaz:
https://doaj.org/article/03d897fd62914e4eb9acda09a2dd28d1